Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Sanara MedTech (SMTI) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Sanara MedTech (SMTI) over the last 15 years, with Q3 2025 value amounting to 11.17%.

  • Sanara MedTech's EBIT Margin rose 75800.0% to 11.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.79%, marking a year-over-year increase of 1600.0%. This contributed to the annual value of 7.75% for FY2024, which is 12600.0% down from last year.
  • Sanara MedTech's EBIT Margin amounted to 11.17% in Q3 2025, which was up 75800.0% from 0.12% recorded in Q2 2025.
  • In the past 5 years, Sanara MedTech's EBIT Margin registered a high of 11.17% during Q3 2025, and its lowest value of 48.52% during Q4 2021.
  • In the last 5 years, Sanara MedTech's EBIT Margin had a median value of 14.31% in 2024 and averaged 15.75%.
  • As far as peak fluctuations go, Sanara MedTech's EBIT Margin plummeted by -307300bps in 2021, and later surged by 281300bps in 2022.
  • Sanara MedTech's EBIT Margin (Quarter) stood at 48.52% in 2021, then soared by 58bps to 20.39% in 2022, then surged by 94bps to 1.28% in 2023, then crashed by -1600bps to 21.72% in 2024, then skyrocketed by 151bps to 11.17% in 2025.
  • Its EBIT Margin was 11.17% in Q3 2025, compared to 0.12% in Q2 2025 and 8.88% in Q1 2025.